Kooij Louise Frederika 4
Research Summary
AI-generated summary
NewAmsterdam (NAMS) CAO Louise Kooij Exercises Options, Sells Shares
What Happened
- Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma (NAMS), exercised stock options to acquire a total of 72,572 shares (38,172 on Jan 23 and 34,400 on Jan 26) at an exercise price of $10.90 per share (total exercise cost $791,035).
- She sold all 72,572 shares in a series of open-market transactions on Jan 23 and Jan 26, 2026, for aggregate gross proceeds of $2,415,843 (sales executed at weighted-average prices shown below). The filing also records the option conversion/disposition entries (reported at $0) associated with the exercises.
- This sequence—exercising options and immediately selling the resulting shares—is effectively a cashless exercise/monetization of vested options (commonly used to cover exercise costs and taxes) and is generally considered routine rather than a directional bet.
Key Details
- Transaction dates: Jan 23, 2026 and Jan 26, 2026; Form 4 filed Jan 27, 2026. No late-filing indication shown in the provided data.
- Options exercised: 38,172 shares (Jan 23) and 34,400 shares (Jan 26) at $10.90 each; total paid ~$791,035.
- Open-market sales (all disposed): 25,405 shares @ $33.44 (proceeds $849,543); 12,767 shares @ $34.37 ($438,802); 34,091 shares @ $32.77 ($1,117,162); 309 shares @ $33.45 ($10,336). Total sales proceeds: $2,415,843. Net proceeds before fees/taxes ≈ $1,624,808.
- Footnotes: sale prices reported as weighted averages with trade ranges: $33.06–$34.05; $34.06–$34.75; $32.40–$33.38; $33.40–$33.51. Option grant dated Jan 1, 2023 with standard vesting (25% at one year, then monthly for three years).
- Shares owned after the transactions: not specified in the provided excerpt of the filing.
Context
- For retail investors: exercises followed by immediate sales are common for executives exercising vested options to cover exercise price and tax withholding; they do not necessarily signal a change in the officer’s view of the company.
- The filing shows an officer monetizing vested options rather than an open-market purchase (which is typically considered a stronger bullish signal).